News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

BioPharm Executive - Bench To Clinic
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates 4/21/2016
Investors Relieved as bluebird bio (BLUE)'s Early Data from Rare Disease Study Looks Positive 4/20/2016
Loxo Oncology (LOXO) TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update 4/18/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies 4/15/2016
Genocea (GNCA) Stock Doubles After Market Yesterday on Positive 12 Months Genital Herpes Data 4/1/2016
Investors are Irked as BioMarin (BMRN)'s Pegvaliase Shows Mixed Results in Pivotal Study 3/21/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study 3/16/2016
GW Pharma (GWPH) Shares Double as Cannabis Drug Meets Goals in Phase III Study 3/15/2016
Regeneron (REGN), Sanofi (SNY)'s RA Drug Beats AbbVie (ABBV)'s Blockbuster Humira in Phase III Study 3/14/2016
Celldex (CLDX) Stock Chokes as Brain Cancer Trial Halted 3/8/2016
Regulus (RGLS) Soars After Promising Hep C Drug Trial Data 2/18/2016
Amgen (AMGN)'s Aranesp Meets Primary Goal in Late Stage Trial 2/16/2016
Incyte (INCY) Stock Tumbles After Halting Another Jakafi Trial for Treating Solid Tumors 2/12/2016
Amgen (AMGN)'s Blincyto Successful in Phase III Leukemia Trial 2/5/2016
Amgen (AMGN)'s Repatha Met Co-Primary Endpoints in Phase III GAUSS-3 Study 2/5/2016
Amgen (AMGN)'s Vectibix + BSC Meets Primary Endpoint in Phase III Study 1/25/2016
Stock Craters as Alkermes (ALKS)' Depression Drug Fails in Two Late-Stage Trials 1/22/2016
Investors Rejoice as Zafgen (ZFGN)'s Obesity Drug Performs Well in Phase III Study, New Data May Lift Clinical Hold 1/21/2016
Man in Coma Dies After Bial's Botched Drug Trial in France, Five Remain Hospitalized 1/19/2016
Dynavax (DVAX) Surges as Hep B Vaccine Meets Goals in Phase III Study 1/7/2016
bluebird bio (BLUE) Stock Plunges After Mixed Report on LentiGlobin Results at American Society of Hematology 12/8/2015
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures 12/7/2015
AbbVie (ABBV) Reveals Positive CLL Data at American Society of Hematology 12/7/2015
Zafgen (ZFGN) Plunges Some More After FDA Orders Full Clinical Hold on Beloranib 12/3/2015
Aduro Biotech (ADRO) Drops After Quietly Disclosing Patient in Top Phase II Program Developed Serious Infection 11/30/2015
Celldex (CLDX) Cancer Vaccine Extends Life for Those With Brain Cancer 11/24/2015
F. Hoffmann-La Roche Ltd. (RHHBY) Release: Combination Of Bevacizumab And Lomustine With First Recurrence Of Glioblastoma Prolongs PFS But Not OS 11/23/2015
Clovis Oncology (CLVS) Plummets on Lung Cancer Drug Review Delay 11/16/2015
Amgen (AMGN)'s ABP 501 Equivalent to Humira in Phase III Rheumatoid Arthritis Study 11/10/2015
Investors Nervous Over bluebird bio (BLUE)'s Latest Gene Therapy Updates Released Ahead of American Society of Hematology Conference 11/9/2015
Biogen (BIIB)'s Natalizumab Did Not Meet Primary and Secondary Endpoints in Late-Stage Study 10/22/2015
bluebird bio (BLUE) Gets Banged Up on Report of Gene Therapy Patient Needing Blood Transfusions 10/21/2015
PTC Therapeutics (PTCT) DMD Drug Fails Trial But Company Says Data is Enough for a FDA Filing 10/16/2015
As Eli Lilly (LLY) Halts CETP Inhibitor Trial, Analyst Wonder if Amgen (AMGN) Wasted $300 Million on Same Class of Drug 10/15/2015
Neurocrine Biosciences (NBIX)'s NBI-98854 Hits Primary Enpoint in Phase III Study 10/9/2015
Amgen (AMGN) and Allergan (AGN)'s Avastin Copycat Succeeds in Late Stage Lung Cancer Study 9/23/2015
Aerie (AERI) Shares Soar After Glaucoma Drug Meets Late Stage Endpoints 9/17/2015
Intra-Cellular Therapies Surges as Schizophrenia Drug Met Primary Endpoint in Phase III 9/17/2015
Novo Nordisk A/S (NVO)’s Victoza Beats Sanofi (SNY)’s Lixisenatide in Head-to-Head Study, Company Says 9/17/2015
Alnylam (ALNY), The Medicines Company (MDCO)'s Long-Acting Cholesterol Drug May Threaten Amgen (AMGN), Regeneron (REGN)-Sanofi (SNY)'s Blockbusters 9/1/2015
NW Bio (NWBO) Temporarily Halts Patient Screening for DCVax-L Brain Cancer Study 8/24/2015
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/20/2015
Genentech (RHHBY)'s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial 8/18/2015
Three Patients Dropped Out of Alnylam (ALNY)'s Phase II Trial for Revusiran 8/7/2015
Sanofi (SNY)'s Lixilan Hits Phase III Goal 7/29/2015
Biogen (BIIB) and Eli Lilly (LLY)’s Alzheimer’s Drugs Hint At Promise, But Fail To Dazzle 7/23/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study 7/21/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News 7/21/2015
Anacor (ANAC) Hits Home Run with Crisaborole Phase III Trials, Predicts $1 Billion Potential Sales 7/15/2015
Genentech (RHHBY)’s Breakthrough Atezolizumab Joins Club of Successful Anti-PD-L1 Drugs, Shrinks Tumors in Bladder Cancer 7/14/2015
SAGE Therapeutics (SAGE) Soars as Postpartum Depression Disappears in Four New Mothers 6/10/2015
ASCO15: Bristol-Myers Squibb (BMY) Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars 6/3/2015
ASCO15: Tiny Clovis Oncology (CLVS) Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women 6/2/2015
ASCO15: Analyst Calls ImmunoGen (IMGN)'s Phase I Ovarian Cancer Data "Impressive" 6/1/2015
ASCO15: Hope Rises As Celldex (CLDX)'s Brain Cancer Vaccine Helps Patients Live Longer 6/1/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/27/2015
Eleven Biotherapeutics (EBIO) Stock Nosedives 80% Premarket as Eye Drug Flunks Phase III Test 5/19/2015
Amgen (AMGN)'s Migraine Drug Meets Goals in Phase II Study 5/19/2015
Genentech (RHHBY) Lung Cancer Treatments Shrink Tumors, Prolong Life 5/15/2015
Puma Biotech (PBYI) Founder Loses $250 Million on Disappointing Breast Cancer Drug Data 5/15/2015
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/22/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/17/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/25/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/20/2015
Novartis AG (NVS)'s Much-Anticipated New Heart Drug May Be Linked to Alzheimer's Disease 2/13/2015
Genentech (RHHBY) Shows Off Positive Phase III Lymphoma Data From Late-Stage Study 2/5/2015
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/21/2015
J.P. Morgan: bluebird bio (BLUE) Soars On CEO's Sickle Cell Data 1/16/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
CytRx Corporation (CYTR)'s Brain Cancer Drug Shows Promise in Mid-Stage Study 1/6/2015
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Eli Lilly (LLY), Incyte Corporation (INCY) Arthritis Drug Meets Endpoint In Phase 3 12/10/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/4/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Phase 2 Data With Revusiran 11/14/2014
Regeneron (REGN), Sanofi (SAN.PA)'s Dual-Action Biotech Asthma Drug Performs Well In Key Test 11/12/2014
Merck & Co. (MRK)'s Four-Week Hep C Regimen With Gilead Sciences, Inc. (GILD)'s Sovaldi Fails To Deliver 11/11/2014
Cardiome Pharma Corp. (COM.TO) Touts Positive Data From Phase 3 BRINAVESS® Trial 11/7/2014
Regulus Therapeutics, Inc. (RGLS) Gets Seat At Hepatitis C Table With Impressive Phase 1 Results 10/22/2014
Celgene (CELG)’s New Crohn’s Disease Drug Impressing Analysts 10/21/2014
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/20/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/22/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (SAN.PA)'s In Phase 3 Trials 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Early Phase 3 Data Suggest Sanofi (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Cambridge-Based bluebird bio (BLUE)'s Gene Therapy Quickly Halts Blood Disease In Small Study; Stock Up 32.08% At Market Close (June 16, 2014) 6/17/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/11/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
Vertex Pharmaceuticals (MA) (VRTX) Reports Positive Ivacaftor Study Data, Plans To Initiate Larger Phase 3 Study 6/4/2014
Gilead Sciences, Inc. (GILD)'s Respiratory Syncytial Virus (RSV) Drug GS-5806 Wows In Phase 2 Trial 5/27/2014
Isis Pharmaceuticals, Inc. (ISIS) Surges As Blood Thinner Drug ISIS-FXI Succeeds In Phase 2 Trial; Stock Up 7.54% At Market Close (May 22, 2014) 5/23/2014
InterMune, Inc. (ITMN) Rises After Fatal Lung Disease Drug Slows Damage In Phase 3 Study 5/20/2014
Mylan Inc. (MYL)'s Necitumumab Improves Overall Survival In Largest Ever Phase 3 Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer 5/15/2014
Vertex Pharmaceuticals (MA) (VRTX) Release: Addition Of VX-661 To KALYDECO® (Ivacaftor) Improves Lung Function In People With CF Who Are Heterozygous For The F508del And G551D Mutations In 28-Day Phase 2 Proof-Of-Concept Study 5/2/2014
One Of A Kind Trial To Test 14 AstraZeneca PLC (AZN), Pfizer Inc. (PFE) Drugs At The Same Time 4/18/2014
Baxter International, Inc. (BAX) Drug BAX 111 Treats 100 Percent Of Bleeding Episodes In Small Phase 3 Trial 4/17/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Endocyte, Inc. (ECYT) Doubles After Drug Shown To Slow Lung Cancer In Phase 2b Study 3/24/2014
Bay Area's InterMune, Inc. (ITMN) Gains As Boehringer Ingelheim Corporation's Rival Drug Shows Mixed Results 3/24/2014
Geron Corporation (GERN) Says FDA Halts Patient Enrollment In Another Cancer Trial 3/21/2014
Amgen (AMGN) Drug Meets Phase 3 Goals For Those With High Genetic Cholesterol 3/18/2014
Intercept Pharmaceuticals (ICPT) Drug Scores Pivotal Phase 3 Win Against Rare Liver Disease 3/18/2014
Raptor Pharmaceutical Inc. (RPTP) Surges As Huntington's Drug Meets Study Endpoints 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials 2/7/2014
Furiex Pharmaceuticals, Inc. (FURX) Shares Double As Irritable Bowel Drug Succeeds In Phase 3 Trials 2/5/2014
AbbVie (ABBV)'s Interferon-Free Hepatitis C Cocktail Excels In Ph3 Study 2/3/2014
ArQule, Inc. (ARQL) Soars As FDA Panel Favors Continuation Of Liver Cancer Drug Study, Stock Up +6.78% At Market Close (January 17, 2014) 1/17/2014
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Surges Following Results Of Phase 2b Eteplirsen Therapy 1/17/2014
As Big Biotech Talks Cancer Vaccines, Bay Area's Aduro Biotech Nails Mid-Stage Pancreatic Cancer Study 1/16/2014
Intercept Pharmaceuticals (ICPT) Falls As CEO Says It May Need Help Big Pharma's Help 1/14/2014
Neurocrine Biosciences, Inc. (NBIX) Rockets On Positive Phase 2 Movement Disorder Drug Data; Stock Up +75.56% At Market Close (January 7, 2014) 1/8/2014
Cubist Pharmaceuticals, Inc. (CBST) Takes Off As Antibiotic Succeeds In Late-Stage Trial 12/18/2013
Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study 12/9/2013
Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC)'s Closely Watched Leukemia Drug Effective In Long Term Study 12/9/2013
Geron Corporation (GERN) Soars After Study Shows Bone Marrow Drug's Benefit 12/9/2013
Eli Lilly and Company (LLY)'s Depression Drug, Edivoxetine, Fails Late-Stage Trials 12/6/2013
Cubist Pharmaceuticals, Inc. (CBST)'s Urinary Tract Infection Drug Succeeds In Phase 3 Study 11/27/2013
Amgen (AMGN)'s Experimental Heart Drug Appears To Be Safe, Cuts LDL By Half At 1 Year Study 11/20/2013
AbbVie (ABBV), Enanta Pharmaceuticals, Inc.'s Hepatitis C Treatment Helps 96 Percent Of Patients In Phase 3 Studies 11/19/2013
GlaxoSmithKline (GSK) Heart Drug Misses Goal In Major Study 11/13/2013
Geron Corporation (GERN) Skyrockets as Cancer Drug is Highly Effective in Trial, Shares Up +44.72% @ Market Close (November 7, 2013) 11/8/2013
Astellas Pharma Inc. (ALPMY), Medivation, Inc. (MDVN) Prostate Cancer Drug Meets Phase 3 Trial Goals 10/22/2013
Ariad Pharmaceuticals, Inc. (ARIA) Discontinues Phase 3 Study of Cancer Drug Iclusig; Shares Decimated, Falls -40.67% at Market Close (October 18, 2013) 10/22/2013
Vertex Pharmaceuticals (MA) (VRTX)'s VX-509 Showed Positive Results for Rheumatoid Arthritis in Phase 2b Study 10/21/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug Slashes Cholesterol in Phase 3 Trial 10/21/2013
Gilead Sciences, Inc. (GILD)'s Idelalisib Works Against Leukemia, Phase 3 Trial Stopped Early; Stock Up +6.42% at Market Close (October 10, 2013) 10/14/2013
GlaxoSmithKline (GSK), ProSensa Holding N.V. (RNA)'s Muscular Dystrophy Drug Fails in Phase 3 Trial; ProSensa Stock Plunges -70.25% at Market Close on September 20, 2013 9/23/2013
Isis Pharmaceuticals, Inc. (ISIS) Rises on Positive Phase 1 Spinal Muscular Data 9/20/2013
Kythera Biopharmaceuticals (KYTH)' Drug Successfully Reduces Double Chin in Studies 9/19/2013
Bristol-Myers Squibb Company (BMY) Prostate Cancer Treatment Falls Short in Phase 3 Trial 9/13/2013
Celgene International Sárl (CELG) Reports POMALYST Met Prrimary Endpoint in Phase 3 Trial 9/5/2013
GlaxoSmithKline (GSK)'s Crohn's Disease Drug Fails Phase 3 Trial, ChemoCentryx, Inc. (CCXI) Stock Falls -32.12% on Friday at Market Close (August 23, 2013) 8/26/2013
Incyte Corporation (INCY) Surges on Positive Phase 2 Pancreatic Cancer Data; Stock Rockets +33.48% Wednesday, August 21, 2013 at Market Close 8/23/2013
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) Up, Then Down, on DMD Competitor's Trial Results 8/21/2013
MannKind Corporation (MNKD) Rockets on Positive Drug Data 8/16/2013
Vertex Pharmaceuticals (MA) (VRTX) Shares Rocket as CF Drug Impresses in Phase 3 Study 8/1/2013
Vertex Pharmaceuticals (MA) (VRTX) Tanks as FDA Puts Hold on Hep C Trial 7/30/2013
Isis Pharmaceuticals, Inc. (ISIS) Drug Reduces Blood Fat by 64 Pct in Phase 2 Study 7/24/2013
Array BioPharma, Inc. (ARRY)'s ARRY-502 Meets Goals in Asthma Study 7/23/2013
Celgene Corporation (CELG)'s Revlimid Improves Survival in Blood Cancer Patients 7/12/2013
Alnylam Pharmaceuticals (ALNY) Reports Positive Top-Line Results for ALN-TTRsc 7/11/2013
Janssen Research & Development's Ibrutinib Monotherapy Shows Efficacy in Patients With MCL or DLBCL 6/17/2013
Amgen (AMGN) Shows Off Phase 3 Ovarian Cancer Data 6/14/2013
Clovis Oncology (CLVS) Shares Almost Double on Cancer Drug Trial 6/4/2013
Merck & Co. (MRK) Melanoma Drug Shrinks Tumors in 38 Percent of Patients: Study 6/4/2013
Alkermes plc (ALKS) Unveils Full Mid-Stage Data on Depression Drug 5/31/2013
Pfizer Inc. (PFE) Halts Study of Non-Hodgkin's Lymphoma Drug 5/29/2013
Bristol-Myers Squibb Company (BMY) Drug Cocktail Stymies Melanoma Tumors 5/17/2013
Experimental Gilead Sciences, Inc. (GILD) Drug Effective in Early-Stage Leukemia Trial 5/16/2013
Infinity Pharmaceuticals Inc. (INFI) Announces Clinical Data to be Presented at American Society of Clinical Oncology and ICML 5/16/2013
Amgen (AMGN) Late-Stage Trial of Colon Cancer Drug Meets Goal 5/10/2013
Vertex Pharmaceuticals Incorporated (VRTX) Booms on Cystic Fibrosis Combo Drug Study 4/23/2013
Alkermes plc (ALKS) Has Jumped to a New High on Study Results 4/17/2013
FDA Asks ACADIA Pharmaceuticals, Inc. (ACAD) to Skip Late Stage Study and File NDA After Successful Results 4/11/2013
GlaxoSmithKline (GSK) Muscular Dystrophy Drug Reaches Primary Objective in Study 4/10/2013
Liver Toxicity Brings Melanoma Study on Bristol-Myers Squibb Company (BMY)/Roche (RHHBY) Drugs to a Halt 4/4/2013
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Injectable MS Drug Cut Relapse Rate by 36 Pct 3/20/2013
Amgen (AMGN)'s Melanoma Drug Shows Promise in Key Trial 3/20/2013
Merck & Co., Inc. (MRK) Says a Crucial Vytorin Study Will Continue 3/13/2013
Celgene Corporation (CELG)'s Apremilast Succeeds in Phase 3 Psoriasis Trial 3/5/2013
FDA Halts Amgen (AMGN) Trial After Teen Death 3/4/2013
AbbVie (ABBV) Suspends Five Clinical Trials of Leukemia Therapy After Patient Deaths 2/27/2013
Genzyme Corporation (GENZ) Touts Positive Ph3 Drug Data 2/19/2013
Gilead Sciences, Inc. (GILD) Sees Positive Results From Late-Stage Hepatitis C Treatment Study 2/19/2013
Eli Lilly and Company (LLY) to Cease Tabalumab Phase 3 RA Program 2/8/2013
Celsion Corporation (CLN)'s Plummets on Phase 3 Liver Cancer Failure 2/1/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Celgene (CELG)'s Abraxane Keeps Pancreatic Pts Alive an Extra Two Months in Trial 1/24/2013
Teva Pharmaceutical Industries Limited (TEVA)'s NUVIGIL® Fails Phase 3 Trial Again 1/23/2013
Genentech (RHHBY) Takes Exelixis, Inc. (EXEL) Drug Into Phase III Melanoma Trial 1/22/2013
The Medicines Company (MDCO) Jumps on Anti-Clotting Drug Study 1/9/2013
Genentech (RHHBY) Preps for $100 Million Alzheimer's Trial 12/19/2012
Oncolytics Biotech Inc. (ONC.TO) Soars on Positive Phase 3 Head and Neck Cancer Data 12/13/2012
Celgene (CELG)'s Pomalidomide Helps in Myeloma After Others Fail 12/12/2012